(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 October 2013 (24.10.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/156488 A2

(51) **International Patent Classification**:
A61K 47/48 (2006.01)

(21) **International Application Number**:
PCT/EP2013/057928

(22) **International Filing Date**:
16 April 2013 (16.04.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

1206628.8	16 April 2012 (16.04.2012)	GB
1213712.1	1 August 2012 (01.08.2012)	GB
1214985.2	22 August 2012 (22.08.2012)	GB

(71) **Applicant**: **LEVERTON LICENCE HOLDINGS LIMITED** [MT/MT]; Palazzo Pietro Stiges, 103 Strait Street, Valletta, VLT1436 (MT).

(72) **Inventors**: **HENRY, William**; Leverton Licence Holdings Limited, Leverton House, 13 Bedford Square, London WC1B 3RA (GB). **WOLF-GARRAWAY, Richard**; Leverton Licence Holdings Limited, Leverton House, 13 Bedford Square, London WC1B 3RA (GB). **MAYO, John Charles**; Leverton Licence Holdings Limited, Leverton House, 13 Bedford Square, London WC1B 3RA (GB). **EARL, Michael James**; Leverton Licence Holdings Limited, Leverton House, 13 Bedford Square, London WC1B 3RA (GB).

(74) **Agents**: **BASSIL, Nicholas** et al.; Kilburn & Strode LLP, 20 Red Lion Street, London WC1R 4PJ (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2013/156488 A2

(54) **Title**: OPTIMISED SUBCUTANEOUS THERAPEUTIC AGENTS

(57) **Abstract**: Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.